TABLE 1.
Descriptive statistics of MPN patients surveyed on infectious complications
| Characteristics | All MPN patients (n = 257) | PV patients (n = 95) | ET patients (n = 125) | MF patients (n = 37) | p value |
|---|---|---|---|---|---|
| Age, years; median (range) | 70 (26–93) | 72 (36–93) | 68 (26–92) | 73 (47–86) | .08 |
| Males; n (%) | 103 (40) | 46 (48) | 36 (29) | 21 (57) | .001 |
| Driver mutation “N” evaluable = 235 (91%) | |||||
| JAK2; n (%) | 197 (84) | 91 (100) | 85 (74) | 21 (72) | |
| CALR; n (%) | 28 (12) | — | 24 (21) | 4 (14) | <.001 |
| MPL; n (%) | 5 (2) | — | 3 (2.5) | 2 (7) | |
| Triple negative; n (%) | 5 (2) | — | 3 (2.5) | 2 (7) | |
| MPN‐related therapy, past 12 months “N” evaluable = 229 (89%) | |||||
| Hydroxyurea; n (%) | 155 (68) | 68 (78) | 82 (75) | 5 (15) | |
| Ruxolitinib; n (%) | 32 (14) | 10 (11) | 3 (3) | 19 (58) | |
| Anagrelide; n (%) | 8 (3) | 1 (1) | 5 (5) | 2 (6) | |
| Interferon; n (%) | 4 (2) | 1 (1) | 3 (3) | 0 (0) | <.001 |
| Busulfan; n (%) | 2 (1) | 0 (0) | 2 (2) | 0 (0) | |
| Multiple/combinations a ; n (%) | 18 (8) | 5 (6) | 10 (9) | 3 (9) | |
| None; n (%) | 10 (4) | 2 (2) | 4 (4) | 4 (12) | |
| Aspirin therapy; n (%) | 201 (78) | 77 (81) | 107 (86) | 17 (46) | <.001 |
| Any infection requiring treatment in past 12 months; n (%) | 86 (33) | 32 (34) | 39 (31) | 15 (41) | .6 |
| Outpatient treatment required for infection in past 12 months | |||||
| >1 infection; n (%) | 29 (11) | 14 (15) | 10 (8) | 5 (14) | |
| 1 infection; n (%) | 48 (19) | 17 (18) | 25 (20) | 6 (16) | .6 |
| None; n (%) | 180 (70) | 64 (67) | 90 (72) | 26 (70) | |
| Inpatient treatment required for infection in past 12 months | |||||
| 1+ infection; n (%) | 12 (5) | 3 (3) | 4 (3) | 5 (14) | |
| None; n (%) | 245 (95) | 92 (97) | 121 (97) | 32 (86) | .06 |
| Infection type | |||||
| ENT b ; n (%) | 23 (9) | 10 (11) | 10 (8) | 3 (8) | .8 |
| Bronchitis; n (%) | 11 (4) | 6 (6) | 5 (4) | 0 (0) | .1 |
| Pneumonia; n (%) | 7 (3) | 2 (2) | 5 (4) | 0 (0) | .2 |
| Gastrointestinal; n (%) | 6 (2) | 1 (1) | 5 (4) | 0 (0) | .1 |
| Skin; n (%) | 16 (6) | 6 (6) | 9 (7) | 1 (3) | .6 |
| Urinary tract; n (%) | 27 (11) | 9 (9) | 14 (11) | 4 (11) | .9 |
| Herpes zoster; n (%) | 13 (5) | 3 (3) | 5 (4) | 5 (14) | .08 |
| Covid‐19; n (%) | 2 (1) | 1 (1) | 1 (1) | 0 (0) | .7 |
| Other c ; n (%) | 18 (7) | 9 (9) | 7 (6) | 2 (5) | .5 |
| Prophylaxis | |||||
| Antibiotic; n (%) | 3 (1) | 0 (0) | 1 (1) | 2 (5) | .06 |
| Antiviral; n (%) | 3 (1) | 1 (1) | 1 (1) | 1 (3) | .7 |
| Antifungal; n (%) | 1 (0.4) | 0 (0) | 1 (1) | 0 (0) | .5 |
| Vaccinations in past 12 months | |||||
| Influenza; n (%) | 115 (45) | 46 (48) | 58 (46) | 11 (29) | .1 |
| Herpes zoster; n (%) | 16 (6) | 8 (8) | 6 (5) | 2 (5) | .5 |
| Pneumococcal; n (%) | 19 (7) | 8 (8) | 9 (7) | 2 (5) | .8 |
| Select concurrent medications Steroids; n (%) | 11 (5) | 3 (4) | 5 (5) | 3 (9) | .5 |
Abbreviations: ET, essential thrombocythemia; ENT, ears nose and throat; MF, myelofibrosis; MPN, myeloproliferative neoplasms; PV, polycythemia vera.
Bold values denotes significant p‐values.
a
Multiple therapies included, either sequentially or in combination: ruxolitinib and anagrelide, ruxolitinib and busulfan, ruxolitinib and hydroxyurea, and hydroxyurea and anagrelide.
b
ENT infections included sinusitis, common cold, and ear infections, among others.
c
Other infections included: bacterial vaginosis, oral candida, dental infections, flu, and epididymitis.